Microbiome Therapeutic Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Microbiome Therapeutic Market size is projected to reach a CAGR of 31.1% from 2023-2030.

The microbiome is a collection of genetic material derived from all of the bacteria that inhabit the human body. When compared to the human genome, the genome of bacteria contains 200 times the number of genes. There are hundreds of distinct bacterial species in the microbiome, with the majority of them found mostly in the mouth, vagina, and mouth. The gut microbiome is a crucial component of the immune system since it aids in the regulation of digestion and the improvement of immunity. The balance of microorganisms is critical since it may lead to weight gain, high cholesterol, excessive blood sugar, and other illnesses if it is out of balance. Industry analysts have examined the technical and commercial business prospects for the Microbiome therapies industry in this highly specialized and expertise-oriented industry research study.

The rising prevalence of obesity is expected to propel the growth of the microbiome therapeutics market. Sedentary lifestyles, busy work lives, and unhealthy food choices are gradually becoming the leading causes of obesity globally. Growing urbanization and busy lifestyles are leading to an increasing preference for packaged and processed foods and physical inactivity. Microbiome therapeutics help prevent and treat diabetes by regulating sugar levels. Increased research and development are key trends gaining popularity in the microbiome therapeutics market. Companies operating in the microbiome therapeutics market are focused on developing new innovations to increase their market share.

On the other hand, problems such as a scarcity of knowledge and insufficient research into the human microbiome are projected to limit the growth of this industry in the future.

Delvens Industry Expert's Standpoint

The microbiome therapeutic market is a rapidly growing field with the potential to revolutionize the treatment of a wide range of diseases. The increasing prevalence of chronic diseases and the growing awareness of the importance of gut health are driving the demand for microbiome-based therapies. The market is expected to witness significant growth in the coming years, with the development of new microbiome-based therapies and the expansion of their applications to a variety of diseases. However, there are also challenges to be addressed, including regulatory hurdles, scientific uncertainty, and the need for more effective clinical trials. Overall, the microbiome therapeutic market holds great promise and represents a significant opportunity for companies and researchers in the biotech and pharmaceutical industries to develop innovative and effective therapies that can improve patient outcomes and quality of life.

Market Portfolio

Key Findings

• The microbiome is a collection of genetic material derived from all of the bacteria that inhabit the human body. When compared to the human genome, the genome of bacteria contains 200 times the number of genes. There are hundreds of distinct bacterial species in the microbiome, with the majority of them found mostly in the mouth, vagina, and mouth. The gut microbiome is a crucial component of the immune system since it aids in the regulation of digestion and the improvement of immunity. The balance of microorganisms is critical since it may lead to weight gain, high cholesterol, excessive blood sugar, and other illnesses if it is out of balance. Industry analysts have examined the technical and commercial business prospects for the Microbiome therapies industry in this highly specialized and expertise-oriented industry research study.
   
• The type segment is further bifurcated into FMT and Microbiome Drugs. Fecal microbiota therapy (FMT) dominated the microbiome therapeutics market in 2021 and is anticipated to dominate the market in the future. The dominance of the segment is attributed to its wide usage in the treatment of C. difficile infection. Moreover, increasing R&D focusing on developments to discover other therapeutic applications of FMT and the introduction of capsules in the market is expected to drive growth.

• The application segment is further segmented into C. difficile, Crohn’s disease, Inflammatory Bowel Disease, Diabetes, and Others. The Clostridium difficile infection (CDI or C. difficile) application segment is projected to expand at the fastest growth rate and will dominate the market in near future. The growth of this segment is attributed to the increasing use of Fecal microbiota transplants (FMT) in the treatment of C. difficile.
   
• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America dominated the market with the largest market share and the region will dominate the market further in the future. Highly established research facilities for the development of novel therapeutics and an increasing target population are the major factors for the dominance of the region.

Regional Analysis

North America to Dominate the Market

• North America dominated the market with the largest market share and the region will dominate the market further in the future.
   
• Highly established research facilities for the development of novel therapeutics and increasing target population are the major factors for the dominance of the region.

Competitive Landscape

• OpenBiome
• Seres Therapeutics Inc.
• 4D Pharma plc.
• Locus Biosciences, Inc.
• Enterome SA
• Finch Therapeutics Group, Inc.
• Intralytix, Inc.
• Microbiotica
• Second Genome
• Rebiotix Inc.
• Vedanta Bioscience, Inc

Recent Developments

• In 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi Medical Co. To help tackle the obesity epidemic, the company’s GoFigure and SlimBiome Medical weight management products will be available in the KSA from early 2022 through the new agreement with Nahdi.
   
• In 2020, 4D Pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and most suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for Microbiome Therapeutic Market so as to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope